Insider Buying: enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires 3,500 Shares of Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Robert Gray purchased 3,500 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were bought at an average price of $2.94 per share, with a total value of $10,290.00. Following the purchase, the director now owns 11,155 shares in the company, valued at $32,795.70. This represents a 45.72 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

enVVeno Medical Stock Performance

NVNO opened at $3.07 on Friday. The firm has a market cap of $53.85 million, a P/E ratio of -2.38 and a beta of 1.22. The business has a 50 day moving average price of $3.16 and a 200 day moving average price of $4.25. enVVeno Medical Corporation has a twelve month low of $2.45 and a twelve month high of $6.97.

enVVeno Medical (NASDAQ:NVNO) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). As a group, analysts anticipate that enVVeno Medical Corporation will post -1.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enVVeno Medical

A number of hedge funds have recently bought and sold shares of the company. Corsair Capital Management L.P. acquired a new position in shares of enVVeno Medical during the 3rd quarter worth about $390,000. Maven Securities LTD acquired a new position in shares of enVVeno Medical during the third quarter worth approximately $295,000. Hohimer Wealth Management LLC bought a new stake in shares of enVVeno Medical in the third quarter valued at approximately $286,000. Westside Investment Management Inc. grew its stake in shares of enVVeno Medical by 128.0% in the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock worth $297,000 after acquiring an additional 49,613 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in enVVeno Medical by 7.8% during the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock worth $506,000 after acquiring an additional 10,902 shares during the period. 34.71% of the stock is currently owned by institutional investors.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).